ReviewThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception2017
Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Review in The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03151005. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Add-on effect of the Guizhi Fuling formula for management of reduced fertility potential in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2022Pooled it
- Trial
- Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial.Health and quality of life outcomes · 2020Trial
- Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial.Journal of ovarian research · 2019Trial
- Effect of orlistat and anti-androgen oral contraceptives on pregnancy outcomes in overweight or obese PCOS patients during comprehensive management.Archives of gynecology and obstetrics · 2026Article
- Exosomes for Polycystic Ovary Syndrome Treatment: Mechanisms and Therapeutic Potential.International journal of nanomedicine · 2026Review
- The role of combined Metformin and pharmaceutical molecules with anti-androgenic properties in the therapy of PCOS in adult women.Endocrine · 2025Review
- Combination of Diane-35 and Cangfu Daotan Wan Effectively Ameliorates Inflammatory Response, Stress State, and Hormone Levels in Patients with Polycystic Ovary Syndrome (PCOS), Leading to Significant Improvement in Clinical Treatment Outcomes.International journal of women's health · 2025Article
- Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial.Therapeutic advances in endocrinology and metabolism · 2025Article
- Clinical effectiveness of ethinylestradiol-cyproterone acetate and raloxifene combination therapy in polycystic ovary syndrome-associated infertility.American journal of translational research · 2025Article
- Discovering therapeutic possibilities for polycystic ovary syndrome by targeting XIST and its associated ceRNA network through the analysis of transcriptome data.Scientific reports · 2024Article
- GIMAP7 induces oxidative stress and apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inhibiting sonic hedgehog signalling pathway.Journal of ovarian research · 2022Article
- Clinical study on polycystic ovary syndrome treated with Diane-35 and Pioglitazone.American journal of translational research · 2021Article
- Phexpo: a package for bidirectional enrichment analysis of phenotypes and chemicals.JAMIA open · 2020Article
- Unveiling Key Biomarkers and Therapeutic Drugs in Polycystic Ovary Syndrome (PCOS) Through Pathway Enrichment Analysis and Hub Gene-miRNA Networks.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPolycystic ovary syndrome (PCOS) is a common, heterogeneous disorder characterised by hyperandrogenic skin symptoms, irregular menstruation and subfertility, increased risk of endometrial malignancy, and increased risk of preventable diseases associated with metabolic syndrome. Cyproterone acetate (CPA) 2 mg, combined with ethinylestradiol (EE) 35 μg, is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age.
objectivesTo review the present knowledge about PCOS and summarize the role of CPA/EE in the care of patients suffering from this condition for the practitioner.
methodsExperts with clinical interest and experience in treating symptoms of androgen excess performed a non-systematic review to provide updated information regarding the use of CPA/EE in patients with PCOS.
resultsPolycystic ovary-related hyperandrogenic skin symptoms are effectively treated by CPA/EE, reducing not only the symptoms but also their negative impact on quality of life and mental health. Proven additional benefits for these patients include the treatment of menstrual irregularities and reduction in endometrial cancer risk. Possible benefits include preservation of fertility. Treatment increases the risk for venous thromboembolic complications. The nature of other metabolic and cardiovascular long-term effects i.e., whether positive or negative, are still to be investigated.
conclusionsCyproterone acetate/ethinylestradiol provides effective treatment for PCO-related hyperandrogenic skin symptoms. This efficacy and additional benefits related to menstrual irregularities and endometrial cancer risk, have to be weighed against the risk of venous thromboembolic complications based on an individual benefit/risk evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.